CASP3 and neoplasm: We found a dose-dependent reduction in MB49 cell viability in vitro (Fig. 5I), confirmed by the enhanced cleaved-caspase-3 levels seen in tumor/stromal cells from JHU083-treated MB49 tumors (Fig. 5J).